Rhythm Pharmaceuticals, Inc.
corporate_fare Company Profile
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 40 items for RYTM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for RYTM spans 10-Q, 8-K.
Recent high-impact activity:
- Two-Year Data: Setmelanotide Holds 18.8% BMI Cut in Hypothalamic Obesity
- Second Bidder Emerges for Rhythm, Lifting Shares 4.2%
- Shares Jump 28% on Reported $124/Share AstraZeneca Bid; NICE Expands IMCIVREE Access
- AstraZeneca Reportedly Made ~$10B Takeover Approach for Rhythm Pharmaceuticals
- Q3 Revenue Up 4% but RYTHM Withholds Q4 Outlook as Federal THC Ban Looms
Financial Snapshot
Short Interest & Short Volume
23.33 days to coverFINRA reported short interest of 11,675,496 shares in RYTM as of the October 30, 2026 settlement, a 6.1% increase from the prior period — about 23.3 days to cover at its recent average daily volume. On November 20, 2026, 35.5% of RYTM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.